Amylyx Pharmaceuticals 将来の成長
Future 基準チェック /06
Amylyx Pharmaceuticalsの収益は年間78.7%で減少すると予測されていますが、年間利益は年間27.7%で増加すると予想されています。EPS は年間34.1%で増加すると予想されています。
主要情報
27.7%
収益成長率
34.1%
EPS成長率
| Pharmaceuticals 収益成長 | 23.6% |
| 収益成長率 | -78.7% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 23 Oct 2024 |
今後の成長に関する最新情報
Recent updates
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Nov 04
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -83 | N/A | -119 | 5 |
| 12/31/2025 | N/A | -106 | N/A | -101 | 6 |
| 12/31/2024 | 88 | -233 | N/A | -139 | 6 |
| 6/30/2024 | 299 | -166 | -60 | -59 | N/A |
| 3/31/2024 | 398 | -71 | 15 | 17 | N/A |
| 12/31/2023 | 381 | 49 | 11 | 12 | N/A |
| 9/30/2023 | 294 | 2 | -53 | -51 | N/A |
| 6/30/2023 | 192 | -73 | -91 | -89 | N/A |
| 3/31/2023 | 94 | -149 | -147 | -144 | N/A |
| 12/31/2022 | 22 | -198 | -182 | -180 | N/A |
| 9/30/2022 | 0 | -184 | -161 | -158 | N/A |
| 6/30/2022 | 0 | -153 | -138 | -136 | N/A |
| 3/31/2022 | 0 | -121 | -103 | -103 | N/A |
| 12/31/2021 | 0 | -88 | -75 | -75 | N/A |
| 9/30/2021 | 1 | -68 | -56 | -55 | N/A |
| 12/31/2020 | 1 | -42 | -37 | -37 | N/A |
| 12/31/2019 | 1 | -14 | -11 | -11 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: AMLX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: AMLX今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: AMLX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: AMLXの収益は今後 3 年間で減少すると予想されています (年間-78.7% )。
高い収益成長: AMLXの収益は今後 3 年間で減少すると予測されています (年間-78.7% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: AMLXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です